All the news Showing 10 of 842 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Coronavirus International registries provide more information about COVID-19 and liver disease Liz Highleyman / 17 September 2020 People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver transplants do not appear to be at greater ... Experimental treatments for NASH/NAFLD Aldafermin reduces liver fat in phase 2 study Keith Alcorn / 14 September 2020 Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting Professor of Hepatology at the University of Oxford, told ... NAFLD Fatty liver disease affects one in four in Europe, study estimates Keith Alcorn / 07 September 2020 Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced liver fibrosis, a meta-analysis of 33 studies from ... Antiviral therapy Stopping antivirals may offer a chance for a hepatitis B cure Liz Highleyman / 06 September 2020 Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair of presentations last week at the 2020 Digital International Liver Congress. This may happen ... Treatment for hepatocellular carcinoma Immunotherapy combinations show promise for advanced liver cancer Liz Highleyman / 02 September 2020 Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer, according to a set of late-breaking presentations last week at the 2020 Digital ... New and experimental treatments for hepatitis B Gilead immune modulator has modest effect on hepatitis B surface antigen Keith Alcorn / 01 September 2020 Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B surface antigen levels in a phase 2 safety and efficacy study presented ... Hepatitis delta Bulevirtide shows promise as maintenance therapy for hepatitis D Liz Highleyman / 30 August 2020 High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to suppression of hepatitis delta virus (HDV), according to a presentation this week at the 2020 Digital International ... New and experimental treatments for hepatitis B JNJ-3989 achieves sustained reductions in hepatitis B surface antigen Keith Alcorn / 29 August 2020 Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when combined with nucleoside analogue drugs, Professor Edward Gane of Auckland City Hospital, New ... New and experimental treatments for hepatitis B GSK antisense agent for hepatitis B shows promise Keith Alcorn / 29 August 2020 An antisense agent, GSK-3228836, significantly reduced hepatitis B surface antigen levels in previously untreated people with chronic hepatitis B after three injections, an early phase trial reported this week at the Digital International ... Hepatitis C elimination Only one in four high-income countries on track for hepatitis C elimination by 2030 Keith Alcorn / 28 August 2020 Only one in four high-income countries is on track to eliminate hepatitis C by 2030 and nearly two-thirds will miss the targets by more than 20 years at current rates of progress, ... ← Prev1...23456...85Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds